keyword
MENU ▼
Read by QxMD icon Read
search

dutasteride

keyword
https://www.readbyqxmd.com/read/28430341/prostate-specific-antigen-increase-during-dutasteride-to-indicate-the-need-for-prostate-biopsy-influence-of-prostatic-inflammation
#1
Alessandro Sciarra, Martina Maggi, Andrea Fasulo, Stefano Salciccia, Vincenzo Gentile, Susanna Cattarino, Alessandro Gentilucci
INTRODUCTION: The aim of this study was to analyze the significance of an increase in total prostate-specific antigen (PSA) serum levels despite dutasteride treatment as a predictor of prostate cancer (PC) at biopsy. We focused our attention on the rate of the first PSA increase and on the influence of prostatic inflammation. METHODS: From 2011 to 2016, 365 men with a previous negative prostate biopsy and persistent elevated PSA levels received dutasteride treatment...
April 4, 2017: Urologia
https://www.readbyqxmd.com/read/28428110/does-peak-urine-flow-rate-predict-the-development-of-incident-lower-urinary-tract-symptoms-in-men-with-mild-to-no-current-symptoms-results-from-reduce
#2
Ross M Simon, Lauren E Howard, Daniel M Moreira, Claus Roehrborn, Adriana Vidal, Ramiro Castro-Santamaria, Stephen J Freedland
PURPOSE: To determine whether decreased peak urine flow is associated with future incident lower urinary tract symptoms (LUTS) in men with mild to no LUTS. MATERIALS AND METHODS: Our population consisted of (3,140) men from the REDUCE trial with mild to no LUTS defined as an International Prostate Symptom Score (IPSS)<8. REDUCE was a randomized trial of dutasteride vs. placebo for prostate cancer prevention in men with an elevated PSA and a negative biopsy. IPSS measures were obtained every 6 months throughout the 4-year study...
April 17, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28426907/frontal-fibrosing-alopecia-clinical-and-prognostic-classification
#3
O M Moreno-Arrones, D Saceda-Corralo, P Fonda-Pascual, A R Rodrigues-Barata, D Buendía-Castaño, A Alegre-Sánchez, C Pindado-Ortega, M Molins, D Perosanz, G Segurado-Miravalles, P Jaén, S Vañó-Galván
BACKGROUND: Frontal fibrosing alopecia (FFA) is a chronic scarring alopecia with an unpredictable evolution. There are no current classifications of this disease that may predict its prognosis. OBJECTIVE: To analyze the differences in clinical presentation and evolution of FFA patients and to create a clinical and prognostic classification METHODS: We conducted a retrospective analytical study of FFA patients. Clinical characteristics of frontal hairline recession were used as the sorting variable between patterns of presentation...
April 20, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28415774/chemoprevention-of-prostate-cancer-in-men-with-high-grade-prostatic-intraepithelial-neoplasia-hgpin-a-systematic-review-and-adjusted-indirect-treatment-comparison
#4
Kang Cui, Xiangnan Li, Yabing Du, Xiance Tang, Seiji Arai, Yiwei Geng, Ying Xi, Han Xu, Yue Zhou, Wang Ma, Tengfei Zhang
BACKGROUND: High-grade prostatic intraepithelial neoplasia (HGPIN) is the precursor or premalignant form of prostate cancer. At least 30% patients with a confirmed HGPIN will develop prostate cancer within 1 year after repeated biopsy. HGPIN patients are the appropriate at-risk population for chemoprevention strategies investigation against prostate cancer. However the commonly used chemoprevention agents that targeted on hormonal imbalance or lifestyle-related factors showed varied results in HGPIN patients...
March 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28412472/preparation-and-characterization-of-dutasteride-loaded-nanostructured-lipid-carriers-coated-with-stearic-acid-chitosan-oligomer-for-topical-delivery
#5
Norhayati Mohamed Noor, Khalid Sheikh, Satyanarayana Somavarapu, Kevin Mg Taylor
Dutasteride, used for treating benign prostate hyperplasia (BPH), promotes hair growth. To enhance delivery to the hair follicles and reduce systemic effects, in this study dutasteride has been formulated for topical application, in a nanostructured lipid carrier (NLC) coated with chitosan oligomer-stearic acid (CSO-SA). CSO-SA has been successfully synthesized, as confirmed using (1)H NMR and FTIR. Formulation of dutasteride-loaded nanostructured lipid carriers (DST-NLCs) was optimised using 2(3) full factorial design...
April 12, 2017: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/28396999/dutasteride-is-associated-with-reduced-risk-of-transrectal-prostate-biopsy-associated-urinary-tract-infection-and-related-hospitalizations
#6
Daniel M Moreira, Gerald L Andriole, J Curtis Nickel, Claus G Roehrborn, Ramiro Castro-Santamaria, Stephen J Freedland
OBJECTIVES: To evaluate whether the use of dutasteride is associated with a lower risk of transrectal prostate biopsy-associated urinary tract infection (TPBA-UTI) among men in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. METHODS: Retrospective analysis of 6045 men undergoing 2-year repeat prostate biopsy in REDUCE. Participants were randomized to receive dutasteride 0.5 mg or placebo daily. TPBA-UTI was defined as the presence of urinary symptoms and the prescription of antibiotics by the treating physician within 30 days after biopsy...
April 10, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/28394496/change-of-ultrasound-estimated-bladder-weight-and-bladder-wall-thickness-after-treatment-of-bladder-outlet-obstruction-with-dutasteride
#7
Ha Na Lee, Young-Suk Lee, Deok Hyun Han, Kyu-Sung Lee
OBJECTIVES: To investigate the change of bladder wall hypertrophy to relieve bladder outlet obstruction (BOO) by treatment with 5α-reductase inhibitor. METHODS: Men who have BOO confirmed by urodynamic study (BOO index ≥40) were treated with dutasteride 0.5 mg once a day for 6 months. We measured ultrasound estimated bladder weight (UEBW), UEBW divided by body surface area (UEBW/BSA), and bladder wall thickness (BWT) before and after treatment. Changes in LUTS parameters were assessed by using the International Prostate Symptom Score, uroflowmetry, residual urine volume, prostate volume, serum prostate-specific antigen (PSA), and LUTS outcome scores (LOS)...
May 2017: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/28384637/dose-dutasteride-reduce-surgical-blood-loss-for-benign-prostatic-hyperplasia-patients-more-information-is-needed
#8
Zheng-Yan Gao
No abstract text is available yet for this article.
April 7, 2017: Urologia Internationalis
https://www.readbyqxmd.com/read/28338531/hormonal-manipulation-with-finasteride-or-oral-contraception-does-not-influence-incidence-of-renal-cell-carcinoma
#9
Aashish Kabra, Jonathan Gelfond, Michael A Liss
Androgens have been suspected to be involved in the initiation of renal cell carcinoma because of a two-fold increased risk in men compared with women. To investigate the role of self-reported finasteride or oral contraceptive use in the Prostate, Lung, Colorectal, and Ovarian (PCLO) to determine whether the androgen receptor reduces renal cancer development. We query the PCLO trial for predictor variables from the baseline questionnaire and follow-up questionnaires enquiring medication use, specifically the use of 5-α reductase inhibitors (dutasteride or finasteride) and oral contraceptive therapy...
March 23, 2017: European Journal of Cancer Prevention
https://www.readbyqxmd.com/read/28319231/association-of-suicidality-and-depression-with-5%C3%AE-reductase-inhibitors
#10
Blayne Welk, Eric McArthur, Michael Ordon, Kelly K Anderson, Jade Hayward, Stephanie Dixon
Importance: There have been concerns raised by patients and regulatory agencies regarding serious psychiatric adverse effects associated with 5α-reductase inhibitors. Objective: To determine if there is an increased risk of suicide, self-harm, or depression among older men starting a 5α-reductase inhibitor for prostatic enlargement. Design, Setting, and Participants: A population-based, retrospective, matched cohort study using linked administrative data for 93 197 men ages 66 years or older (median [IQR] age, 75 [70-80] years) in Ontario, Canada, who initiated a new prescription for a 5α-reductase inhibitor during the study period (2003 through 2013)...
March 20, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28294070/dutasteride-in-androgenetic-alopecia-an-update
#11
Tasleem Arif, Konchok Dorjay, Mohammad Adil, Marwa Sami
BACKGROUND: Androgenetic alopecia is a common condition characterized by thinning of scalp hair. Conversion of testosterone to dihydrotestosterone, a more potent androgen, by the enzyme 5-a-reductase is responsible for underlying pathogenesis. Dutasteride, a synthetic 4-azasteroid, is a selective and competitive inhibitor of both type-1 and type-2 isoenzymes of 5-alpha-reductase. Finasteride and minoxidil are the only approved drugs for androgenetic alopecia. Dutasteride has been demonstrated to be effective in several randomized, double-blind, placebo controlled trials in androgenetic alopecia...
March 10, 2017: Current Clinical Pharmacology
https://www.readbyqxmd.com/read/28289563/persistent-erectile-dysfunction-in-men-exposed-to-the-5%C3%AE-reductase-inhibitors-finasteride-or-dutasteride
#12
Tina Kiguradze, William H Temps, Paul R Yarnold, John Cashy, Robert E Brannigan, Beatrice Nardone, Giuseppe Micali, Dennis Paul West, Steven M Belknap
IMPORTANCE: Case reports describe persistent erectile dysfunction (PED) associated with exposure to 5α-reductase inhibitors (5α-RIs). Clinical trial reports and the manufacturers' full prescribing information (FPI) for finasteride and dutasteride state that risk of sexual adverse effects is not increased by longer duration of 5α-RI exposure and that sexual adverse effects of 5α-RIs resolve in men who discontinue exposure. OBJECTIVE: Our chief objective was to assess whether longer duration of 5α-RI exposure increases risk of PED, independent of age and other known risk factors...
2017: PeerJ
https://www.readbyqxmd.com/read/28261678/early-dutasteride-monotherapy-in-men-with-detectable-serum-prostate-specific-antigen-levels-following-radical-prostatectomy-a-prospective-trial
#13
Yu Seob Shin, Jea Whan Lee, Myung Ki Kim, Young Beom Jeong, Seung Chol Park
PURPOSE: To investigate the effects of early administration of dutasteride in patients with detectable serum prostate-specific antigen (PSA) levels after radical prostatectomy (RP). MATERIALS AND METHODS: A prospective open-label study, with a cumulative analysis of asymptomatic increase in PSA following RP, was conducted from January 2005 to December 2013. An early increase in PSA level was defined as detectable serum PSA level> 0.04 ng/mL. Patients with PSA level>0...
March 2017: Investigative and Clinical Urology
https://www.readbyqxmd.com/read/28257560/dutasteride-add-on-therapy-reduces-detrusor-mass-in-patients-with-benign-prostatic-enlargement-not-satisfied-with-alpha-adrenergic-antagonist-monotherapy-a-single-center-prospective-study
#14
Cosimo De Nunzio, Aldo Brassetti, Flavia Proietti, Mauro Gacci, Sergio Serni, Francesco Esperto, Andrea Tubaro
AIMS: The ultrasound assessment of bladder wall thickness (BWT) and intravesical prostatic protrusion (IPP) have emerged as a non-invasive, inexpensive, time-saving alternatives to pressure-flow studies to assess benign prostatic obstruction (BPO). Aim of our study was to evaluate the effect on detrusor mass of dutasteride add-on therapy in men with lower urinary tract symptoms (LUTS) and benign prostatic enlargement (BPE). METHODS: A consecutive series of BPE patients with a prostate volume (PV) ≥30 mL and an international prostate symptoms score (IPSS) ≥8 not satisfied with Tamsulosin monotherapy were enrolled...
March 3, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28228662/risk-of-gynecomastia-and-breast-cancer-associated-with-the-use-of-5-alpha-reductase-inhibitors-for-benign-prostatic-hyperplasia
#15
Katrina Wilcox Hagberg, Hozefa A Divan, Shona C Fang, J Curtis Nickel, Susan S Jick
BACKGROUND: Clinical trial results suggest that 5-alpha reductase inhibitors (5ARIs) for the treatment of benign prostatic hyperplasia (BPH) may increase the risk of gynecomastia and male breast cancer, but epidemiological studies have been limited. PATIENTS AND METHODS: We conducted a cohort study with nested case-control analyses using the UK Clinical Practice Research Datalink. We identified men diagnosed with BPH who were free from Klinefelter syndrome, prostate, genital or urinary cancer, prostatectomy or orchiectomy, or evidence of gynecomastia or breast cancer...
2017: Clinical Epidemiology
https://www.readbyqxmd.com/read/28208224/percent-decrease-of-serum-prostate-specific-antigen-after-dutasteride-administration-is-equivalent-in-men-with-clinical-benign-prostatic-hyperplasia-having-baseline-prostate-specific-antigen-10-ng-ml-and-those-having-baseline-prostate-specific-antigen-2-5-10
#16
Hideki Takeshita, Satoru Kawakami, Akihiro Yano, Yohei Okada, Makoto Morozumi, Takumi Yamada
No abstract text is available yet for this article.
February 16, 2017: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/28151719/neoadjuvant-enzalutamide-prior-to-prostatectomy
#17
Bruce Montgomery, Maria S Tretiakova, Anthony M Joshua, Martin E Gleave, Neil Fleshner, Glenn J Bubley, Elahe A Mostaghel, Kim N Chi, Daniel W Lin, Martin Sanda, William Novotny, Kenneth Wu, Philip W Kantoff, Brett T Marck, Stephen Plymate, Steven P Balk, Peter S Nelson, Alvin M Matsumoto, Rosina T Lis, Adam Kibel, Gabriel P Haas, Andrew Krivoshik, Alison Hannah, Mary-Ellen Taplin
Purpose: Prostate cancer is dependent on androgen receptor (AR) activation. Optimal AR antagonism may effectively cytoreduce local disease and suppress or eliminate micrometastases. We evaluated neoadjuvant therapy prior to prostatectomy with the potent AR antagonist enzalutamide (enza) either alone or in combination with dutasteride (dut) and leuprolide (enza/dut/luteinizing hormone-releasing hormone analogues [LHRHa]).Experimental Design: Forty-eight of 52 men with intermediate or high-risk localized prostate cancer proceeded to prostatectomy after neoadjuvant enzalutamide or enza/dut/LHRHa for 6 months...
November 9, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28145028/effects-of-steroidal-antiandrogen-or-5-alpha-reductase-inhibitor-on-prostate-tissue-hormone-content
#18
Yasuhiro Shibata, Seiji Arai, Yoshiyuki Miyazawa, Takahiro Shuto, Masashi Nomura, Yoshitaka Sekine, Hidekazu Koike, Hiroshi Matsui, Kazuto Ito, Kazuhiro Suzuki
BACKGROUND: The effects of a steroidal antiandrogen (AA) and 5-alpha-reductase inhibitor (5ARI) on prostate tissue hormone content and metabolism are not fully elucidated. The objective of this study is to investigate the hormone content and metabolism of the prostate tissues of patients treated with AA or 5ARI using the ultra-sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. METHODS: Thirty-nine patients with benign prostatic hyperplasia (BPH) undergoing transurethral surgery were included...
February 1, 2017: Prostate
https://www.readbyqxmd.com/read/28127948/bioequivalence-studies-of-a-reformulated-dutasteride-and-tamsulosin-hydrochloride-combination-capsule-and-a-commercially-available-formulation
#19
Renee Kurczewski, Chet Bowen, David Collins, John Zhu, Gulyeter Serbest, Michael Manyak
A dutasteride 0.5 mg and tamsulosin hydrochloride 0.4 mg combination (DTC) capsule (Duodart(®) ) was reformulated to reduce the capsule size and enhance product stability. Bioequivalence of the reformulated DTC capsule with the commercial formulation was evaluated in 2 single-dose, open-label, randomized, 2-way crossover studies in healthy adult male volunteers. Subjects in a fasted or fed state received a single oral dose of either the reformulated DTC or the commercial formulation followed by a 28-day washout period between treatments...
January 27, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28102554/what-are-the-predicting-factors-for-the-therapeutic-effects-of-dutasteride-in-male-patients-with-lower-urinary-tract-symptoms-investigation-using-a-urodynamic-study
#20
Yoshihisa Matsukawa, Masashi Kato, Yasuhito Funahashi, Tsuyoshi Majima, Tokunori Yamamoto, Momokazu Gotoh
AIMS: We investigated predicting factors for the therapeutic effects of dutasteride in patients with lower urinary tract symptoms (LUTS) due to benign prostatic enlargement (BPE) based on a urodynamic study (UDS). METHODS: This was a single-center, prospective study involving 120 male outpatients with LUTS. They received 0.5 mg of dutasteride per day for 12 months. IPSS, OABSS, IPSS-QOL, and UDS were used for assessing subjective and objective symptoms prior to and 12 months after administration...
January 19, 2017: Neurourology and Urodynamics
keyword
keyword
43774
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"